Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: A pooled analysis of 4 clinical trials

被引：3

作者：

Choueiri, Toni K. ^{[1
]}

Ghatalia, Pooja ^{[2
]}

de Velasco, Guillermo ^{[3
]}

Albiges, Laurence ^{[4
]}

Burotto, Mauricio ^{[5
]}

Suarez, Cristina ^{[6
]}

Brugarolas, James ^{[7
]}

Iacovelli, Roberto ^{[8
]}

Jalkanen, Katriina ^{[9
]}

Lam, Elaine T. ^{[10
]}

Srinivasan, Ramaprasad ^{[11
]}

Merchan, Jaime ^{[12
]}

Agarwal, Neeraj ^{[13
]}

Iversen, Ane B. ^{[14
]}

Rini, Brian ^{[15
]}

Bauer, Todd M. ^{[16
]}

Gurney, Howard ^{[17
]}

Iliopoulos, Othon ^{[18
,19
]}

Lin, Jianxin ^{[20
]}

Starkopf, Liis ^{[20
]}

Donica, Margarita ^{[20
]}

Gumieniak, Olga ^{[20
]}

Vickery, Donna ^{[20
]}

Liu, Yanfang ^{[20
]}

Perini, Rodolfo F. ^{[20
]}

Powles, Thomas ^{[21
]}

Jonasch, Eric ^{[22
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Fox Chase Canc Ctr, Philadelphia, PA USA

[3] Univ Hosp 12 Octubre, Madrid, Spain

[4] Inst Gustave Roussy, Med Oncol Dept, Villejuif, France

[5] Bradford Hill Clin Res Ctr, Santiago, Chile

[6] Hosp Univ Vall Dhebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[7] Univ Texas Southwestern Med Ctr Dallas, Internal Med Hematol Oncol, Dallas, TX USA

[8] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[9] HUS Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland

[10] Univ Colorado Anschutz Med Campus, Univ Colorado Canc Ctr, Aurora, CO USA

[11] NCI, Ctr Canc Res, Bethesda, MD USA

[12] Univ Miami Hosp & Clin, Sylvester Canc Ctr, Canc Res Serv, Oncol, Miami, FL USA

[13] Huntsman Canc Inst, Clin Translat Canc Res Genitourinary Oncol Progra, Salt Lake City, UT USA

[14] Aarhus Univ Hosp, Aarhus, Denmark

[15] Vanderbilt Ingram Canc Ctr, Nashville, OH USA

[16] Greco Hainsworth Ctr Res Tennessee Oncol PLLC, Nashville, TN USA

[17] Macquarie Univ, Oncol, Sydney, NSW, Australia

[18] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[19] Harvard Med Sch, Boston, MA USA

[20] Merck & Co Inc, Rahway, NJ USA

[21] Barts Hlth NHS Trust, St Bartholomews Hosp, London, England

[22] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

ONCOLOGIST | 2024年 / 29卷

关键词：

Belzutifan; HIF-2a; renal cell carcinoma;

D O I：

10.1093/oncolo/oyae181.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[1] IN-DEPTH CHARACTERIZATION OF THE SAFETY PROFILE OF BELZUTIFAN MONOTHERAPY IN PATIENTS WITH RENAL CELL CARCINOMA: A POOLED ANALYSIS OF FOUR CLINICAL TRIALS
Eric, Jonasch
Pooja, Ghatalia
Guillermo, de Velasco
Laurence, Albiges
Mauricio, Burotto
Cristina, Suarez
James, Brugarolas
Roberto, Iacovelli
Katriina, Jalkanen
Elaine, T. Lam
Ramaprasad, Srinivasan
Jaime, Merchan
Neeraj, Agarwal
Ane, B. Iversen
Brian, Rini
Todd, M. Bauer
Howard, Gurney
Othon, Iliopoulos
Lin, Jianxin
Liis, Starkopf
Margarita, Donica
Olga, Gumieniak
Donna, Vickery
Yanfang, Liu
Rodolfo, F. Perini
Thomas, Powles
Toni, K. Choueiri
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
[2] SAFETY OF ACALABRUTINIB MONOTHERAPY IN MATURE B-CELL TUMORS: POOLED ANALYSIS OF CLINICAL TRIALS
De la Serna, Javier
Furman, Richard R.
Byrd, John C.
Owen, Roger G.
O'Brien, Susan M.
Brown, Jennifer R.
Hillmen, Peter
Stephens, Deborah M.
Baek, Marshall
Christian, Belth
Dyer, Martin J. S.
Streetly, Matthew J.
Sun, Clare
Rule, Simon
Wang, Michael
Ghia, Paolo
Jurczak, Wojciech
Pagel, John M.
Sharman, Jeff P.
HAEMATOLOGICA, 2020, 105 : 68 - 68
[3] Safety profile of bempedoic acid: pooled analysis of 4 phase 3 clinical trials
Ballantyne, C. M.
Banach, M.
Catapano, A. L.
Duell, P. B.
Laufs, U.
Leiter, L. A.
Mancini, G. B. J.
Ray, K. K.
Bloedon, L. T.
Sasiela, W. J.
Ye, Z.
Bays, H. E.
EUROPEAN HEART JOURNAL, 2019, 40 : 3257 - 3257
[4] Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, Jeffrey S.
Hodi, F. Stephen
Wolchok, Jedd D.
Topalian, Suzanne L.
Schadendorf, Dirk
Larkin, James
Sznol, Mario
Long, Georgina V.
Li, Hewei
Waxman, Ian M.
Jiang, Joel
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 785 - +
[5] Safety of Acalabrutinib Monotherapy in Hematologic Malignancies: Pooled Analysis From Clinical Trials
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 9 - 10
[6] Safety of Acalabrutinib Monotherapy in Hematologic Malignancies: Pooled Analysis From Clinical Trials
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 2 - 4
[7] EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Belzutifan for Renal Cell Carcinoma
Khrystolubova, Natasha
ONCOLOGY-NEW YORK, 2022, 36 (01): : 64 - 65
[8] The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis
Ge Song
Song Xue
Yingming Zhu
Chunling Wu
Xiaowei Ji
BMC Pharmacology and Toxicology, 25 (1)
[9] Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
Song, Yuqin
Xu, Wei
Song, Yongping
Liu, Lihong
Lin, Song
Li, Zhiming
Liu, Ting
Yi, Shuhua
Zhou, Daobin
Zhang, Mingzhi
Hu, Yu
Jin, Jie
Zhu, Huaqiang
Lu, Zhengguang
Zhao, Renbin
Xu, Zhixin
Zhu, Jun
BLOOD, 2020, 136
[10] Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma:a meta-analysis
Fei Qin
Hao Yu
Changrong Xu
Huihui Chen
Jianling Bai
TheJournalofBiomedicalResearch, 2018, 32 (01) : 30 - 38

← 1 2 3 4 5 →